Immunohistochemistry can now detect FH protein deficiency in leiomyoma tissue, which represents either a germline mutation associated with HLRCC or a somatic mutation within the leiomyoma. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.